Hainan Steou Investment

Hainan Steou Investment is a Chinese biopharmaceutical company focused on the development of innovative small molecule therapeutics for metabolic and chronic diseases. Operating primarily through its subsidiary, Hainan Steou Pharmaceutical, the company maintains a research and development pipeline centered on high-value indications such as non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Its lead clinical candidate, ST-001, is a selective thyroid hormone receptor beta (THR-beta) agonist currently undergoing Phase 2 clinical evaluation. The company leverages the strategic advantages of the Hainan Free Trade Port to integrate drug discovery, clinical development, and investment. Hainan Steou aims to address significant unmet medical needs in hepatology and endocrinology through targeted molecular design.